We analyzed the specificity and robustness of this phenomenon as a drug target candidate, summarized recent efforts in exploiting macropinocytosis for drug delivery into KRAS mutant cancer, and discussed the opportunities, challenges and pitfalls of this strategy. This evidence concerns the gene KRAS and cancer.